Automatic Parallel Peptide Synthesiser Market Forecasts to 2030 - Global Analysis By Type (Fully-Automatic and Semi-Automatic), Application and By Geography

According to Stratistics MRC, the Global Automatic Parallel Peptide Synthesiser Market is accounted for $601 million in 2023 and is expected to reach $1127 million by 2030 growing at a CAGR of 9.4% during the forecast period. A specialized tool used in biology and chemistry for the automated synthesis of peptides is an automatic parallel peptide synthesizer. Proteins are mostly made up of peptides, which are short chains of amino acids. Peptide synthesizers are tools used by scientists and researchers to manufacture precise amino acid sequences for use in medication development, protein studies, and biochemical research, among other uses. Certain synthesizers may be equipped with integrated peptide purification and analysis functions, such as mass spectrometry or high-performance liquid chromatography (HPLC).

Market Dynamics:

Driver:

Rising demand for peptide-based therapeutics

Pharmaceuticals made from peptides or proteins are referred to as "peptide-based therapeutics," which also includes peptide medications and biologics. They are becoming more and more well-known in the biotechnology and pharmaceutical sectors because of their special benefits, which include reduced toxicity and higher specificity than conventional small molecule medications. High target specificity is a well-known characteristic of peptide-based therapies thus they may be engineered to engage with particular proteins, cells, or receptors. Moreover, custom-designed peptides produced by automated parallel peptide synthesizers are becoming more and more necessary as the need for more individualized and focused therapies rises.

Restraint:

Lack of availability of a skilled workforce

The requirement for a highly qualified labor may make it difficult for startups, smaller research institutions, and enterprises with tight funds to get started. These organizations can find it difficult to draw in and keep people with the right kind of experience and it can take a lot of time and money to train people to operate automated synthesizers and perform peptide synthesis. Businesses that depend significantly on skilled workers may experience difficulties if important individuals depart or are unavailable where reliance on a small number of people might result in dangers and interruptions to operations thereby hindering the growth of the market.

Opportunity:

Growing focus on personalized medicine

Treating patients according to their unique genetic and molecular profiles is the goal of personalized medicine. It is possible to create peptides that specifically target and interact with genetic variants or biomarkers linked to a patient's illness. Rapid and effective synthesis of peptides tailored to a patient is made possible by automatic parallel peptide synthesizers. The distinct genetic and biochemical features of each person's illness can be catered for by customizing these peptides. It is now feasible to detect certain genetic variants and mutations linked to illnesses because to developments in genomics and DNA sequencing thus peptides that precisely target these genetic markers can be created using automatic peptide synthesizers which propels the market growth.

Threat:

Technological obsolescence

Older synthesizers might not have the same features, functionalities, or efficiency as more recent versions. Manufacturers of older synthesizers may face less competition as a result of consumers who are drawn to the newest innovations and may be discouraged from investing in antiquated machinery. It's possible that accessories and software from more recent generations of synthesizers won't work with earlier models, which would restrict capacity to utilize the newest features and link your equipment with other lab systems and instruments.

COVID-19 Impact

Research into antiviral peptides, which are essential for creating cures and vaccinations, was expedited by the epidemic. The need for peptide synthesizers to produce antiviral peptides arose as a result thus the need for peptide synthesis equipment was fueled by the COVID-19 vaccines' quick development, several of which contain peptides in their formulations. Organizations are investigating automation and remote monitoring of equipment, particularly peptide synthesizers, due to the necessity for distant work and social isolation. Moreover, increasing government support for vaccine production and research connected to COVID-19 made it possible to purchase peptide synthesizers.

The fully-automatic segment is expected to be the largest during the forecast period

The fully-automatic segment is estimated to have a lucrative growth, as these peptide synthesis processes may be handled concurrently by fully-automatic synthesizers, allowing for high-throughput peptide manufacturing. Peptide synthesis is guaranteed by these synthesizers because they provide exact control over reaction parameters like temperature, duration, and reagent concentrations. Furthermore high-performance liquid chromatography (HPLC) and mass spectrometry are two integrated purification and analysis features that certain fully-automatic synthesizers offer, making it possible to produce pure peptides quickly thus encouraging in the market expansion.

The medical segment is expected to have the highest CAGR during the forecast period

The medical segment is anticipated to witness the highest CAGR growth during the forecast period, because the medical-grade automatic parallel peptide synthesizers are specialist tools made to meet the specific requirements of the healthcare and medical industries. The automated synthesis of peptides of medical significance, such as those employed in medication development, diagnostic tests, and therapeutic applications, is the main usage for these synthesizers. Medical research use vaccinations based on peptides to elicit immune responses. The peptide components of these vaccines must be synthesized automatically using automatic synthesizers.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the biotechnology, pharmaceutical, and life sciences sectors which are seeing a significant increase in research and development activity in the Asia-Pacific area. These studies heavily rely on peptide synthesis, which fuels the need for automated parallel peptide synthesizers. Peptide synthesizers are becoming more and more in demand because to advancements in biotechnology such as genomics, proteomics, and customized medicine, these advancements are being used to biomarker identification, the creation of diagnostic assays, and individualized peptide therapeutics.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to Research & development for pharmaceuticals which are concentrated in Europe. The area is actively involved in several drug research and discovery initiatives, many of which entail the synthesis of biologics and peptide-based medications. Numerous businesses offering bespoke peptide synthesis services are based in Europe. Additionally, due to the increasing number of collaborations between pharmaceutical corporations from other areas and European research institutes is driving up the demand for sophisticated equipment for peptide synthesis.

Key players in the market

Some of the key players profiled in the Automatic Parallel Peptide Synthesiser Market include: Activotec, MultiSynTech GmbH, CEM GmbH, Biotage, AAPPTEC, PolyPeptide Group, CreoSalus, AnproTech Inc., Telegenixx, Almac Group and Next Pharma Inc.

Key Developments:

In June 2023, Biotage completes the acquisition of Astrea Bioseparations and resolves on a share issue to the Sellers as part of the acquisition. The acquisition also includes the shares held by certain minority investors in the Astrea group.

In March 2021, Activotec collaborated with Coronex to develop a game-changing platform for lateral flow (LF) tests that could be vital in the fight against COVID-19. This proprietary platform technology has been used to develop highly optimised LF tests for SARS-Cov-2 antibodies.

In February 2021, MultiSynTech GmbH and Biotage AB join forces and enter the peptide synthesis business. The agreements with MultiSynTech will grant Biotage distribution rights for all current MultiSynTech peptide synthesis systems.

Types Covered:

• Fully-Automatic
• Semi-Automatic

Applications Covered:

• Medical
• Laboratory
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances